A petition for public consent has been filed to urge the health insurance coverage of HER2 (Human Epithelial Cell Growth Factor Receptor 2) low-expression breast cancer treatment Enhurtu, which is set to be approved for marketing in Korea. The petitioner, who recently filed a petition through the National Assembly, introduced to the Yoon Seok-yeol government that the cost of the Enhurtu vaccination in Korea is about 80 million won, expressing the need for domestic permission and medical insurance.

More than 4,000 people have agreed to the petition, which expires on the 29th.

Enhurtu is an anti-cancer drug jointly developed by Daiichi Sankyo and AstraZeneca as an antibody-drug conjugate (A